1. Find new tests in blood, urine, semen, or biopsy (or surgery) samples that can tell if a patient has prostate cancer.
2. Find tests that can identify aggressive cancers.
To discover these tests, blood, urine, semen and clinical information from close to 4000 men are required. We plan to enroll patients over a period of 5 years in Calgary and Edmonton.
In Calgary, recruitment will occur at the Prostate Cancer Centre and Tom Baker Cancer Centre. In addition, participants may join the study by contacting the Calgary study coordinator at 403-943-8942.
In Edmonton, recruitment will occur at the Northern Alberta Urology Centre and Cross Cancer Institute. In addition, participants may join the study by contacting the Edmonton study coordinator at 780-407-5914.
Ask your doctor if you are eligible to participate in the study!
Download the Alberta Prostate Registry and Biorepository Information Brochure.
Download the Alberta Prostate Cancer Registry and Biorepository Information Brochure.
Cancer Control Alberta reduces the impact of cancer on all Albertans and provides expert care and support for patients from their first symptom to survivorship. Supporting world-class research are two specialized teams that operate within the Clinical Trials Units at the Cross Cancer Institute and the Tom Baker Cancer Centre. Each team provides well-trained staff and comprehensive services to researchers who are conducting clinical trials. In addition to the cancer centres, The Prostate Cancer Centre in Calgary and the Northern Alberta Urology Centre in Edmonton are testing advances in diagnosis and treatment to improve quality of life and work towards a cure for prostate cancer.
Our fall APCaRI 2018 symposium wrapped up on Saturday afternoon after two days of excellent seminars, great food, lots of coffee, bowling, hikes around Banff, get-togethers at the local pub, and beautiful fall weather with minimal snowfall!
The APCaRI meeting was attended by people from across Canada and the USA representing the Alberta Cancer Foundation, Bird Dogs for Prostate Cancer Research, Cross Cancer Institute, DynaLIFE Medical Labs, Edmonton Health City, Entos Pharmaceuticals, Institute of Health Economics, Nanostics Inc, Northern Alberta Urology Centre, Oisin Biotechnologies, PandiaDX, PROSTAID Calgary, Prostate Cancer Centre, Prostate Cancer Support Group, University of Alberta, University of Calgary, Western University, and the Yukon Hospital Corporation.
The invited speakers gave excellent keynote talks that kick-started interesting conversations during the meeting.
Dr. Alison Allan from Western University gave the Friday keynote seminar on developing circulating tumour cells as liquid biospies for early detection of cancers.
Dr. Melina Cimler, CEO of PandiaDX, and Saturday’s keynote speaker, outlined the potentially complex regulatory pathways that molecular diagnostic companies need to navigate when pursuing regulation in the USA.
Thank you to Rume Djebah for organizing the 2018 APCaRI Fall Symposium!